Serum levels of insulin-like growth factor I, II, and binding protein 3, transforming growth factor β-1, soluble Fas ligand and superoxide dismutase activity in stomach cancer cases and their controls in the JACC study

Journal of Epidemiology

Volumn 15, Issue SUPPL. 2, 2005, Pages

  Yatsuya, Hiroshi ^a   Toyoshima, Hideaki ^a   Tamakoshi, Koji ^a   Tamakoshi, Akiko ^a   Kondo, Takaaki ^b   Hayakawa, Norihiko ^c   Sakata, Kiyomi ^d   Kikuchi, Shogo ^e   Hoshiyama, Yoshiharu ^f,r   Fujino, Yoshihisa ^g,h   Mizoue, Tetsuya ⁱ   Tokui, Noritaka ^h   Yoshimura, Takesumi ^h,j   Mori, Mitsuru ^k   Motohashi, Yutaka ^l   Tsuji, Ichiro ^m   Nakamura, Yosikazu ⁿ   Iso, Hiroyasu ^o   Mikami, Haruo ^p   Inaba, Yutaka ^q   Suzuki, Hiroshi ^s   Shimizu, Hiroyuki ^t   Wakai, Kenji ^u   Tokudome, Shinkan ^v   Ito, Yoshinori ^w   Hashimoto, Shuji ^x   Koizumi, Akio ^y   Kawamura, Takashi ^y   Watanabe, Yoshiyuki ^z   Miki, Tsuneharu ^z   Date, Chigusa ^aa   Nose, Takayuki ^ab   Shibata, Akira ^ac   Okamoto, Naoyuki ^ad   Shio, Hideo ^ae   Ohno, Yoshiyuki ^af   Kitagawa, Tomoyuki ^ag   Kuroki, Toshio ^ah   Tajima, Kazuo ^u   more..

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^e AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g Fukuoka Institute of Occupational Health   (Japan)

^h UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

ⁱ KYUSHU UNIVERSITY   (Japan)

^j FUKUOKA INSTITUTE OF HEALTH AND ENVIRONMENTAL SCIENCES   (Japan)

^k SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^m TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁿ JICHI MEDICAL UNIVERSITY   (Japan)

^o UNIVERSITY OF TSUKUBA   (Japan)

^p CHIBA CANCER CENTER   (Japan)

^q JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^r UNIVERSITY OF HUMAN ARTS AND SCIENCES   (Japan)

^s NIIGATA UNIVERSITY   (Japan)

^t GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^u AICHI CANCER CENTER HOSPITAL   (Japan)

^v NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^w FUJITA HEALTH UNIVERSITY   (Japan)

^x FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^y KYOTO UNIVERSITY   (Japan)

^z KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^aa MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

^ab TOTTORI UNIVERSITY   (Japan)

^ac KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^ad KANAGAWA CANCER CENTER   (Japan)

^ae Moriyama Municipal Hospital   (Japan)

^af Asahi Rosai Hospital   (Japan)

^ag CANCER CHEMOTHERAPY CENTER   (Japan)

^ah GIFU UNIVERSITY   (Japan)

more..

Author keywords

Helicobacter pylori; IGFs; sFas; SOD; Stomach neoplasms; TGF 1

Indexed keywords

FAS LIGAND; FASLG PROTEIN, HUMAN; MEMBRANE PROTEIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SUPEROXIDE DISMUTASE; TGFB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; FEMALE; HUMAN; JAPAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; STOMACH TUMOR;

ADULT; AGED; CASE-CONTROL STUDIES; FAS LIGAND PROTEIN; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; JAPAN; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 26244436238     PISSN: 09175040     EISSN: 13499092     Source Type: Journal    
DOI: 10.2188/jea.15.S120     Document Type: Article

References (20)

1. Plummer M, Franceschi S, Munoz N. Epidemiology of gastric cancer. IARC Sci Publ. 2004; 157: 311-26.
2. Lambert R, Guilloux A, Oshima A, Pompe-Kirn V, Bray F, Parkin M, et al. Incidence and mortality from stomach cancer in Japan, Slovenia and the USA. Int J Cancer 2002; 97: 811-8.
3. Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawina P, et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998; 392: 402-5.
4. Ebert MPA, Yu J, Miehlke S, Fei G, Lendeckel U, Ridwelski K, et al. Expression of transforming growth factor beta-1 in gastric cancer and in the gastric mucosa of first-degree relatives of patients with gastric cancer. Br J Cancer 2000; 82: 1795-800.
5. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002; 109: 113-24.
6. Rothman KJ, Greenland S. Case-Control studies. In: Rothman KJ, Greenland S Eds. Modem Epidemiology, 2nd ed. Lippincott-Raven Publishers, Philadelphia, 1998: 93-114.
7. Ohno Y, Tamakoshi A; JACC Study Group. Japan collaborative cohort study for evaluation of cancer risk sponsored by Monbusho (JACC study). J Epidemiol 2001; 11: 144-50.
8. Yatsuya H, Toyoshima H, Mizoue T, Kondo T, Tamakoshi K, Hori Y, et al. Family history and the risk of stomach cancer death in Japan: differences by age and gender. Int J Cancer. 2002; 97: 688-94.
9. Yatsuya H. Toyoshima H, Tamakoshi A, Kikuchi S, Tamakoshi K, Kondo T, et al. Individual and joint impact of family history and Helicobacter pylori infection on the risk of stomach cancer: a nested case-control study. Br J Cancer 2004; 91: 929-34.
10. Ohyanagi Y. Establishment of nitrite-kit for SOD activity determination. Ensho, 1984; 4: 63-73. (in Japanese)
11. Lim SC. Expression of Fas ligand and sFas ligand in human gastric adenocarcinomas. Oncol Rep 2002; 9: 103-7.
12. Doi T, Nishikawa Y, Endo H, Hosokawa Y, Tanimizu M, Hyodo I. Serum soluble Fas antigen in gastric MALT (mucosa-associated lymphoid tissue) lymphorna patients. J Exp Clin Cancer Res 1999; 18: 343-5.
13. Martin JH, Potthoff A, Ledig S, Cornberg M, Jandl O, Marnns MP, et al. Effect of H. pylori on the expression of TRAIL, FasL and their receptor subtypes in human gastric epithelial cells and their role in apoptosis. Helicobacter 2004; 9: 371-86.
14. Lin Y, Kikuchi S, Obata Y, Yagyu K. Serum copper/zinc superoxide dismutase (Cu/Zn SOD) and gastric cancer risk: a case-control study. Jpn J Cancer Res 2002; 93: 1071-5.
15. Zhang ZW, Newcomb PV, Moorghen M, Gupta J, Feakins R, Savage P, et al. Insulin-like growth factor binding protein-3: relationship to the development of gastric pre-malignancy and gastric adenocarcinoma (United Kingdom). Cancer Causes Control. 2004; 15: 211-8.
16. Franciosi CM, Piacentini MG, Conti M, Romano F, Musco F, Caprotti R, et al. IGF-1 and IGF-1BP3 in gastric adenocarcinoma. Preliminary study. Hepatogastroenterology. 2003; 50: 297-300.
17. Taha AS, Beastall G, Morton R, Park RH, Beattie AD. Insulin-like growth factor-I in Helicobacter pylori gastritis and response to eradication using bismuth based triple therapy. J Clin Pathol 1996; 49: 676-8.
18. Saito H, Tsujitani S, Oka S, Kondo A, Ikeguchi M, Maeta M, et al. An elevated serum level of transforming growth factor-beta 1 (TGF-beta 1) significantly correlated with lympli node metastasis and poor prognosis in patients with gastric carcinoma. Anticancer Res 2000; 20: 4489-93.
19. Niki M, Okajima K, Isozaki H, Toyoda M, Ichinona T, Nomura E, et al. Measurement of the plasma transforming growth factor-beta 1 (TGF-beta 1) level in patients of gastric carcinoma: compared with the serum IAP level and the lymphocyte subsets (CD3, CD4, CD8). Nippon Shokakibyo Gakkai Zasshi. 1996;93:303-11. (in Japanese)
20. Maehara Y, Kakeji Y, Kabashima A, Emi Y, Watanabe A, Akazawa K, et al. Role of transforming growth factor-beta 1 in invasion and metastasis in gastric carcinoma. J Clin Oncol 1999; 17: 607-14.